Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C

Journal of Hepatology

Volumn 34, Issue 5, 2001, Pages 748-755

  Bruno, Savino ^a   Battezzati, Pier Maria ^a   Bellati, Giorgio ^b   Manzin, Aldo ^c   Maggioni, Marco ^a   Crosignani, Andrea ^a   Borzio, Mauro ^d   Solforosi, Laura ^c   Morabito, Alberto ^e   Ideo, Gaetano ^f   Podda, Mauro ^a  

^a Dept Med Surg Dent Sch M   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

^e Ist di Stat Medica e Biometria   (Italy)

^f San Giuseppe Hospital   (Italy)

Author keywords

Chronic hepatitis C; Clinically relevant outcomes; Interferon; Liver histology; Long term study; Sustained response

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 0034998785     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00062-9     Document Type: Article

References (36)

1. Liang T.J. Combination therapy for hepatitis C infection. N Engl J Med. 339:1998;1549-1550.
2. Cammà C., Giunta M., Pinzello G., Morabito A., Verderio P., Pagliaro L. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol. 94:1999;581-595.
3. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 341:1999;556-562.
4. Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.M. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 31:2000;777-782.
5. Bonis P.A., Ioannidis J.P., Cappelleri J.C., Kaplan M.M., Lau J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology. 26:1997;1035-1044.
6. Cammà C., Giunta M., Linea C., Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation by meta-analysis. J Hepatol. 26:1997;1187-1199.
7. Sobesky R., Mathurin P., Charlotte F., Moussalli J., Olivi M., Vidaud M., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology. 116:1999;378-386.
8. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 132:2000;517-524.
9. Chemello L., Cavalletto L., Casarin C., Bonetti P., Bernardinello E., Pontisso P., et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med. 124:1996;1058-1060.
10. Marcellin P., Boyer N., Gervais A., Martinot M., Pouteau M., Castelnau C., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med. 127:1997;875-881.
11. Larghi A., Tagger A., Crosignani A., Ribero M.L., Bruno S., Portera G., et al. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. J Med Virol. 55:1998;7-11.
12. Koff R.S. Interferon-alpha for chronic hepatitis C: reducing the uncertainties. Ann Intern Med. 127:1997;918-920.
13. Kowdley K. Interferon alfa for chronic hepatitis C: how do we define cure? Gastroenterology. 115:1998;501-502.
14. Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
15. Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 27:1998;1394-1402.
16. Serfaty L., Aumaitre H., Chazouilleres O., Bonnan A-M., Rosmorduc O., Poupon R.E., et al. Determinants of outcome of compensated HCV-related cirrhosis. Hepatology. 27:1998;1435-1440.
17. Imai Y., Kawata S., Tamura S., Yabuuchi I., Noda S., Inada M., et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 129:1998;94-99.
18. Pagliaro L., Craxì A., Cammà C., Tinè F., Di Marco V., Lo Iacono O., Almasio P. Interferon-α for chronic hepatitis C: an analysis of pre-treatment clinical predictors of response. Hepatology. 19:1994;820-828.
19. Bruno S., Borzio M., Battezzati P.M. Interferon-alpha in chronic hepatitis C. Letter Ann Intern Med. 128:1998;956.
20. Ideo G., Bellati G., Leandro G. Recombinant alpha-2a interferon versus lymphoblastoid interferon versus no treatment for chronic hepatitis C: a prospective controlled trial. Dianzani F. Lymphoblastoid interferon. Current aspects and future perspectives. Proceedings of the first international symposium on lymphoblastoid alfa-interferon; May 1992; Porto Cervo, Italy. 1992;54-60 Current Medical Literature, London.
21. Battezzati P.M., Podda M., Bruno S., Zuin M., Crosignani A., Camisasca M., et al. Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. Ital J Gastroenterol. 24:1992;70-73.
22. Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
23. Manzin A., Bagnarelli P., Menzo S., Giostra F., Brugia M., Francesconi R., et al. Quantitation of hepatitis C virus genome molecules in plasma samples. J Clin Microbiol. 32:1994;1939-1944.
24. Okamoto H., Sugijama Y., Okada S., Kurai K., Akahane Y., Sugai Y., et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 73:1992;673-679.
25. Silini E., Bono F., Cerino A., Piazza V., Solcia E., Mondelli M.U. Virological features of hepatitis C virus infection in hemodialysis patients. J Clin Microbiol. 31:1993;2913-2917.
26. Simmonds P., Alberti A., Alter H.J., Bonino F., Bradley D.W., Brechot C., et al. A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology. 19:1994;1321-1324.
27. Knodell R.G., Ishak G.K., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
28. Matthews J.N.S., Altman D.G., Campbell M.J., Royston P. Analysis of serial measurements in medical research. Br Med J. 300:1990;230-235.
29. Reichard O., Glaumann H., Fryden A., Norkrans G., Schvarcz R., Sonnerborg A., et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon α-2b treatment. Hepatology. 21:1995;918-922.
30. Cammà C., Di Marco V., Lo Iacono O., Almasio P., Giunta M., Fuschi P., et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol. 28:1998;531-537.
31. Lau D.T-Y., Kleiner D.E., Ghany M.G., Park Y., Schmid P., Hoofnagle J.H. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology. 28:1998;1121-1127.
32. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol. 31:(Suppl 1):1999;25-30.
33. Haydon G.H., Jarvis L.M., Blair C.S., Simmonds P., Harrison D.J., Simpson K.J., Hayes P.C. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut. 42:1998;570-575.
34. Weiland O. Can HCV infection be cleared? Lancet. 352:1998;669-670.
35. Di Bisceglie A.M. Natural history of hepatitis C: its impact on clinical management. Hepatology. 31:2000;1014-1018.
36. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 318:1988;1728-1733.